IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
IMUNON, Inc. (NASDAQ: IMNN) has announced a conference call scheduled for August 14, 2024, at 11:00 a.m. ET to discuss its second quarter 2024 financial results and provide updates on its clinical development programs. The company will focus on two key areas:
1. IMNN-001: A DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for first-line, locally advanced-stage ovarian cancer.
2. PlaCCine modality: A proprietary DNA plasmid and synthetic DNA delivery technology for expressing pathogen antigens in next-generation vaccine development.
Interested parties can join the call via phone or webcast, with replay options available until August 28, 2024.
IMUNON, Inc. (NASDAQ: IMNN) ha annunciato una conferenza telefonica programmata per 14 agosto 2024, alle 11:00 ET per discutere i suoi risultati finanziari del secondo trimestre 2024 e fornire aggiornamenti sui suoi programmi di sviluppo clinico. L'azienda si concentrerà su due aree chiave:
1. IMNN-001: Un'immunoterapia a base di DNA interleuchina-12 (IL-12) in fase di sviluppo clinico Fase 2 per il trattamento del cancro ovarico localmente avanzato in prima linea.
2. Modalità PlaCCine: Una tecnologia proprietaria di plasmide DNA e di consegna di DNA sintetico per l'espressione di antigeni patogeni nello sviluppo di vaccini di nuova generazione.
Le parti interessate possono partecipare alla chiamata tramite telefono o webcast, con opzioni di riproduzione disponibili fino al 28 agosto 2024.
IMUNON, Inc. (NASDAQ: IMNN) ha anunciado una llamada de conferencia programada para el 14 de agosto de 2024, a las 11:00 a.m. ET para discutir sus resultados financieros del segundo trimestre de 2024 y proporcionar actualizaciones sobre sus programas de desarrollo clínico. La compañía se centrará en dos áreas clave:
1. IMNN-001: Una inmunoterapia basada en ADN interleucina-12 (IL-12) en desarrollo clínico en fase 2 para el cáncer de ovario localmente avanzado en primera línea.
2. Modalidad PlaCCine: Una tecnología propietaria de plásmido de ADN y entrega de ADN sintético para expresar antígenos patógenos en el desarrollo de vacunas de nueva generación.
Las partes interesadas pueden unirse a la llamada por teléfono o webcast, con opciones de repetición disponibles hasta el 28 de agosto de 2024.
IMUNON, Inc. (NASDAQ: IMNN)는 2024년 8월 14일 오전 11시 ET에 예정된 컨퍼런스 콜을 발표했습니다. 이 행사에서는 2024년 2분기 재무 결과를 논의하고 임상 개발 프로그램에 대한 업데이트를 제공할 예정입니다. 회사는 두 가지 주요 분야에 초점을 맞출 것입니다:
1. IMNN-001: 1차 치료로 국소 진행성 난소암에 대한 2상 임상 개발 중인 DNA 기반 인터루킨-12 (IL-12) 면역요법.
2. PlaCCine 모달리티: 차세대 백신 개발을 위해 병원체 항원을 발현하는 것을 위한 독점 DNA 플라스미드 및 합성 DNA 전달 기술.
관심 있는 당사자는 전화 또는 웹캐스트를 통해 콜에 참여할 수 있으며, 재생 옵션은 2024년 8월 28일까지 제공됩니다.
IMUNON, Inc. (NASDAQ: IMNN) a annoncé une conférence téléphonique prévue pour le 14 août 2024 à 11h00 ET pour discuter de ses résultats financiers du deuxième trimestre 2024 et fournir des mises à jour sur ses programmes de développement clinique. L'entreprise se concentrera sur deux domaines clés :
1. IMNN-001: Une immunothérapie basée sur l'ADN interleukine-12 (IL-12) en développement clinique de phase 2 pour le cancer de l'ovaire avancé localement en première ligne.
2. Modalité PlaCCine: Une technologie propriétaire de plasmide ADN et de livraison d'ADN synthétique pour exprimer des antigènes pathogènes dans le développement de vaccins de nouvelle génération.
Les parties intéressées peuvent rejoindre l'appel par téléphone ou par webinaire, avec des options de rediffusion disponibles jusqu'au 28 août 2024.
IMUNON, Inc. (NASDAQ: IMNN) hat eine Konferenzschaltung für den 14. August 2024 um 11:00 Uhr ET angekündigt, um die Finanzergebnisse des 2. Quartals 2024 zu besprechen und Updates zu seinen klinischen Entwicklungsprogrammen zu geben. Das Unternehmen wird sich auf zwei wesentliche Bereiche konzentrieren:
1. IMNN-001: Eine DNA-basierte Interleukin-12 (IL-12) Immuntherapie, die sich in klinischer Entwicklung der Phase 2 für fortgeschrittenen, lokal fortgeschrittenen Ovarialkrebs in der Erstlinientherapie befindet.
2. PlaCCine-Modus: Eine proprietäre DNA-Plasmid- und synthetische DNA-Übertragungstechnologie zur Expression von pathogenetischen Antigenen in der Entwicklung von Impfstoffen der nächsten Generation.
Interessierte Parteien können sich telefonisch oder per Webcast an der Konferenzschaltung beteiligen, eine Wiederholung ist bis zum 28. August 2024 verfügbar.
- IMUNON is progressing with Phase 2 clinical development of IMNN-001 for ovarian cancer
- The company is developing a proprietary DNA plasmid technology for next-generation vaccines
- None.
LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.
To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Second Quarter 2024 Earnings Call. A live webcast of the call will also be available here.
The call will be archived for replay until August 28, 2024, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 1829664. An audio replay of the call will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions, and to further strengthen IMUNON’s balance sheet through attractive business development opportunities. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
| Contacts: | |
| IMUNON | LHA Investor Relations |
| David Gaiero | Kim Sutton Golodetz |
| 978-376-6352 | 212-838-3777 |
| dgaiero@imunon.com | kgolodetz@lhai.com |
# # #
FAQ
When is IMUNON (IMNN) releasing its Q2 2024 financial results?
What clinical programs will IMUNON (IMNN) discuss in its Q2 2024 update?
How can investors access IMUNON's (IMNN) Q2 2024 earnings call?
Until when will the replay of IMUNON's (IMNN) Q2 2024 earnings call be available?
